The negative trailing P/E reflects the 2025Q3 net loss of roughly $711.8M, which appears driven by non-recurring items rather than core operations, so trailing multiples are not meaningful here. The forward P/E of 18.53 sits below Thermo Fisher's 38.16 and Danaher's 44.91, suggesting investors are discounting Avantor relative to higher-margin peers. Investors should monitor whether the forward estimate holds, since the implied recovery depends on sustained operating margin improvement from current levels near 7% to 8%.

Gross margin has held in a narrow 31.5% to 34.1% band, which is comparable to Thermo Fisher but well below Danaher, suggesting the gap is concentrated below the gross profit line in operating expenses. The volatility in net margin, which ranged from roughly 2% to above 29% across periods, indicates that headline net income is heavily affected by non-operating items. Operating margin is therefore the more reliable gauge of true earning power, and it appears structurally constrained relative to peers.

The low ROIC is consistent with a large goodwill-heavy asset base, where goodwill of roughly $4.9B to $5.8B represents a large share of total assets and dilutes returns. The 2024Q4 spike to 4.8% ROIC appears tied to a one-time gain rather than sustained improvement, so it should not be extrapolated. Investors should monitor whether margin recovery is sufficient to lift returns meaningfully above the cost of capital.

The reduction in leverage suggests debt service is becoming more comfortable, but the 0.01 debt-to-equity reading in 2026Q2 appears anomalous and warrants further investigation rather than being treated as a genuine structural change. Interest coverage near 2x to 3x leaves limited cushion if operating income softens, and the data does not disclose covenant terms or refinancing schedules. Based on the figures supplied, leverage appears manageable but not conservative.